Skip to content
20-F

Annual Report (Foreign)

Nasus Pharma Ltd NSRX

0001493152-26-012559

← back to feed
Filed
Mar 25, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 8.01M sh
Shares Diluted FY 2025 · Dec 31, 2024 7.03M sh
Shares Diluted FY 2025 · Dec 31, 2023 7.06M sh
Shares Outstanding FY 2025 · Dec 31, 2025 9.02M sh
Capex FY 2025 · Dec 31, 2025 $14K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$4.92M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$665K
Operating Cash Flow FY 2025 · Dec 31, 2023 −$1.03M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.24M
Cash And Equivalents FY 2025 · Dec 31, 2024 $284K
Cash And Equivalents FY 2025 · Dec 31, 2023 $193K
Stockholders Equity FY 2025 · Dec 31, 2025 $2.77M
Stockholders Equity FY 2025 · Dec 31, 2024 −$3.21M
Stockholders Equity FY 2025 · Dec 31, 2023 −$3.8M
Stockholders Equity FY 2025 · Dec 31, 2022 −$2.79M
Current Liabilities FY 2025 · Dec 31, 2025 $2.16M
Current Liabilities FY 2025 · Dec 31, 2024 $3.93M
Total Liabilities FY 2025 · Dec 31, 2025 $2.24M
Total Liabilities FY 2025 · Dec 31, 2024 $3.93M
Current Assets FY 2025 · Dec 31, 2025 $4.86M
Current Assets FY 2025 · Dec 31, 2024 $457K
Total Assets FY 2025 · Dec 31, 2025 $5M
Total Assets FY 2025 · Dec 31, 2024 $717K
Eps Diluted FY 2025 · Dec 31, 2025 −$0.72
Eps Diluted FY 2025 · Dec 31, 2024 −$0.22
Eps Diluted FY 2025 · Dec 31, 2023 −$0.20
Eps Basic FY 2025 · Dec 31, 2025 −$0.72
Eps Basic FY 2025 · Dec 31, 2024 −$0.22
Eps Basic FY 2025 · Dec 31, 2023 −$0.15
Sga Expense FY 2025 · Dec 31, 2025 $2.67M
Sga Expense FY 2025 · Dec 31, 2024 $743K
Sga Expense FY 2025 · Dec 31, 2023 $580K
Rd Expense FY 2025 · Dec 31, 2025 $2.24M
Rd Expense FY 2025 · Dec 31, 2024 $335K
Rd Expense FY 2025 · Dec 31, 2023 $567K
Net Income FY 2025 · Dec 31, 2025 −$5.86M
Net Income FY 2025 · Dec 31, 2024 −$1.53M
Net Income FY 2025 · Dec 31, 2023 −$1.05M
Operating Income FY 2025 · Dec 31, 2025 −$4.9M
Operating Income FY 2025 · Dec 31, 2024 −$1.08M
Operating Income FY 2025 · Dec 31, 2023 −$1.15M
Revenue FY 2025 · Dec 31, 2025 $1.24B